Sort
10,766 grants matching “checkpoint inhibitor”
Novel therapeutics for targeting checkpoint dysfunction in cancer
$363,346Weei-Chin Lin · Baylor College Of Medicine · R01 · FY2024 · CA
Project 1
$363,288Mark M. Awad · Dana-Farber Cancer Inst · P50 · FY2022 · CA
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy
$363,204Drew M. Pardoll · Johns Hopkins University · R01 · FY2019 · CA
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
$363,165Don Lynn Gibbons · University Of Tx Md Anderson Can Ctr · R37 · FY2023 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers
$363,164Faye Johnson · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis
$363,164Florencia McAllister · University Of Tx Md Anderson Can Ctr · R37 · FY2023 · CA
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$363,164Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$363,164Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01
$363,164Melody A Swartz · University Of Chicago · R01 · FY2022 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers
$363,164Faye Johnson · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Toward understanding the role of altered glycosylation in cancer
$363,139Stacy Alyse Malaker · Yale University · R35 · FY2022 · GM
Reprogramming of the stromal microenvironment in melanoma progression and therapeutic escape
$363,124Yuhang Zhang · University Of Cincinnati · R01 · FY2025 · CA
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma
$363,090Roger S Lo · University Of California Los Angeles · R01 · FY2023 · CA
Targeted therapies in cutaneous melanoma
$363,090Andrew E Aplin · Thomas Jefferson University · R01 · FY2023 · CA
Targeted therapies in cutaneous melanoma
$363,090Andrew E Aplin · Thomas Jefferson University · R01 · FY2022 · CA
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma
$363,090Roger S Lo · University Of California Los Angeles · R01 · FY2022 · CA
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
$363,090Andrew E Aplin · Thomas Jefferson University · R01 · FY2022 · CA
Replication checkpoint and genomic fidelity in skin
$362,918Massachusetts General Hospital · R01 · FY2003 · AR
The replication checkpoint and genomic fidelity in skin
$362,918Massachusetts General Hospital · R01 · FY2004 · AR
USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center
$362,836Andrew Abba Stolz · University Of Southern California · U01 · FY2023 · DK
Lung Cancer Vaccine
$362,579Nasser Khaled Altorki · Weill Medical Coll Of Cornell Univ · U54 · FY2022 · CA
Targeting GLI-dependent Transcription by GANT61 in Colon Cancer
$362,569Janet Anne Houghton · Cleveland Clinic Lerner Com-Cwru · R01 · FY2015 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer
$362,569Weei-Chin Lin · Baylor College Of Medicine · R01 · FY2017 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer
$362,569Weei-Chin Lin · Baylor College Of Medicine · R01 · FY2018 · CA
Inter-regulatory function of immune-modulation and angiogenesis in cancer
$362,569Gabriele Bergers · University Of California, San Francisco · R01 · FY2017 · CA